Adjuvant pembrolizumab-related hyperprogression in stage III melanoma

J Dtsch Dermatol Ges. 2021 Sep;19(9):1341-1345. doi: 10.1111/ddg.14535. Epub 2021 Jul 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Humans
  • Melanoma* / drug therapy
  • Melanoma* / pathology
  • Neoplasm Staging
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab